[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632066":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":21,"id":51,"slug":21,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":21,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":21,"enrollmentInfo":59,"targetDuration":21,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":73,"overallStatus":34,"whyStopped":21,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Eligible participants","EXPERIMENTAL","Sequential \\[18F\\]-FDG PET\u002FCT and \\[68Ga\\]Ga-PFD3 PET\u002FCT",[13,14],"Diagnostic Test: Sequential [18F]-FDG PET\u002FCT","Diagnostic Test: [68Ga]Ga-PFD3 PET\u002FCT scan",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DIAGNOSTIC_TEST","Sequential [18F]-FDG PET\u002FCT","Based on individual clinical circumstances, eligible patients will undergo sequential \\[18F\\]FDG PET\u002FCT and \\[68Ga\\]Ga-PFD3 PET\u002FCT scans within one week.",[9],null,{"type":17,"name":23,"description":19,"armGroupLabels":24,"otherNames":21},"[68Ga]Ga-PFD3 PET\u002FCT scan",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":21,"email":30},"Tingting Yuan, M. D.","CONTACT","+86-13051707479","biluohtt@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Peking university first hospital nuclear medicine","RECRUITING","Beijing","Beijing Municipality","100034","China",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":29,"phoneExt":21,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Tingting Yuan","Attending physician","100632066",false,"NCT07508852","68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer","Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET\u002FCT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Adults.\n* Histologically confirmed small cell lung cancer (SCLC).\n* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.\n* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Breastfeeding.\n* Acute psychiatric disorders.\n* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).\n* Inability to complete the study procedures as anticipated.\n* Prior therapy targeting DLL3.","ALL","18 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE1","PHASE2","This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).",[68,69,70,71,72],"SCLC","SCLC, Extensive Stage","SCLC, Limited Stage","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )",[68,74,75,76,77,78,79,80,81],"small cell lung cancer","PET\u002FCT","PET","DLL3","Delta-like ligand 3","imaging","diagnosis","evaluation","2026-06-16",{"date":84,"type":85},"2026-06-18","ACTUAL",{"date":87,"type":85},"2025-10-22",{"date":89,"type":61},"2027-12-31",{"name":5,"class":6},1]